Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17136608 | Methods and Compositions for Treating Autophagy Related Disease States and Conditions Utilizing AMPK Activation | December 2020 | June 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17130936 | INJECTABLE FORMULATIONS FOR TREATING CANCER | December 2020 | October 2023 | Abandon | 33 | 2 | 1 | Yes | No |
| 17129399 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | December 2020 | November 2022 | Allow | 23 | 1 | 1 | No | No |
| 17128397 | Method for Isolating Cellulose- or Chitin-Nanocrystals by Means of Periodate Oxidation | December 2020 | February 2022 | Allow | 14 | 0 | 0 | No | No |
| 17254674 | ORAL COMPOSITION | December 2020 | March 2024 | Allow | 39 | 1 | 0 | No | No |
| 17251964 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | December 2020 | March 2024 | Allow | 39 | 2 | 0 | No | No |
| 15734499 | SULFUR-CONTAINING GLYCANS AND POLYSACCHARIDES AND METHODS OF CHEMOENZYMATIC SYNTHESIS THEREOF | December 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17059318 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | November 2020 | February 2022 | Allow | 14 | 1 | 0 | No | No |
| 17056829 | NANOFIBRILLAR CELLULOSE HYDROGEL | November 2020 | April 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 16950350 | BIOFILM PENETRATING COMPOSITIONS AND METHODS | November 2020 | September 2021 | Allow | 10 | 0 | 1 | Yes | No |
| 16956612 | PREPARATION METHOD OF HIGH-PURITY TOTAL GINKGO FLAVONOL GLYCOSIDE AND APPLICATION OF SAME | November 2020 | April 2022 | Allow | 22 | 1 | 1 | No | No |
| 17052187 | A PROCESS FOR THE PREPARATION OF ESSENTIAL OILS MODIFIED NANOCELLULOSE AND APPLICATION THEREOF | October 2020 | April 2022 | Allow | 17 | 1 | 0 | No | No |
| 17078789 | METHODS OF TREATING TUMOR METASTASIS | October 2020 | January 2022 | Allow | 15 | 1 | 0 | No | No |
| 17049905 | AMIDITE COMPOUND AND METHOD FOR PRODUCING POLYNUCLEOTIDE USING SAID COMPOUND | October 2020 | April 2022 | Allow | 18 | 0 | 0 | No | No |
| 17061670 | SYNTHETIC DISUGAR HYDROCARBONS AS NATURAL ANALOGS TO CONTROL MICROBIAL BEHAVIORS | October 2020 | January 2022 | Allow | 16 | 1 | 0 | No | No |
| 17044534 | COMBINATION OF A CANNABINOID AND A CHEMOTHERAOPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER | October 2020 | January 2023 | Allow | 28 | 2 | 0 | No | No |
| 17044310 | PROCESS FOR THE PREPARATION OF IRON (III) CARBOXYMALTOSE | September 2020 | June 2023 | Abandon | 32 | 2 | 1 | No | No |
| 17034672 | ACETYLATION OF ALOE POLYSACCHARIDES | September 2020 | August 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16981986 | METHOD FOR SYNTHESIZING SUCROSE-6-ESTER | September 2020 | August 2021 | Allow | 11 | 0 | 0 | No | No |
| 16979972 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | September 2020 | March 2023 | Allow | 30 | 2 | 1 | No | No |
| 16979108 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | September 2020 | August 2023 | Abandon | 36 | 2 | 1 | Yes | No |
| 16978418 | A HIGH CAPACITY PLATFORM FOR IMMUNOGENIC CANCER CELL DEATH | September 2020 | January 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17003377 | COMPOSITION COMPRISING HYALURONIC ACID AND MEPIVACAINE | August 2020 | April 2022 | Allow | 19 | 1 | 0 | No | No |
| 16341460 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | August 2020 | March 2022 | Abandon | 35 | 0 | 1 | No | No |
| 16943939 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | July 2020 | May 2022 | Allow | 22 | 2 | 0 | No | No |
| 16966398 | STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES | July 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 16941674 | ANTITUMOR AGENT FOR BILIARY TRACT CANCER AND METHOD FOR TREATING BILIARY TRACT CANCER | July 2020 | April 2021 | Allow | 8 | 1 | 0 | No | No |
| 16941627 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | July 2020 | December 2020 | Allow | 5 | 1 | 0 | No | No |
| 16940451 | POLYMORPHIC COMPOUNDS AND USES THEREOF | July 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16965023 | Potent sialyltransferase inhibitors | July 2020 | December 2022 | Allow | 29 | 2 | 1 | No | No |
| 16964401 | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA | July 2020 | June 2023 | Allow | 34 | 2 | 1 | No | No |
| 16964149 | COMPOSITIONS FOR USE TO TREAT CATARACT | July 2020 | July 2022 | Allow | 24 | 1 | 0 | No | No |
| 16961247 | Spontaneous Nucleic Acid Purification and Concentration In A Single Step | July 2020 | May 2024 | Allow | 47 | 1 | 1 | No | No |
| 16957793 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | June 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16956723 | COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION IN INFANTS AND YOUNG CHILDREN | June 2020 | February 2022 | Allow | 20 | 1 | 0 | No | No |
| 16954491 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | June 2020 | March 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 16771717 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(�-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATE9 | June 2020 | September 2021 | Allow | 15 | 1 | 0 | No | No |
| 16898365 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | June 2020 | December 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16896823 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | June 2020 | August 2021 | Allow | 14 | 0 | 0 | No | No |
| 16770482 | MEDICAMENT FOR PREVENTION OF TREATMENT OF RHINOVIRUS INFECTION | June 2020 | April 2022 | Allow | 23 | 1 | 1 | No | No |
| 16769527 | POLYSACCHARIDE DERIVATIVE | June 2020 | November 2021 | Allow | 18 | 1 | 1 | No | No |
| 16768350 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | May 2020 | September 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16767489 | PHARMACEUTICAL COMPOSITION COMPRISING ADENOSINE DERIVATIVE FOR PREVENTION AND TREATMENT OF RETINAL DISEASE OR OPTIC NERVE DISEASE | May 2020 | May 2023 | Abandon | 36 | 2 | 0 | No | No |
| 16765427 | METHOD OF SYNTHESISING 6-DEOXY-6-AMINO-�-D-GLUCOPYRANOSIDE-CONTAINING POLYMERS AND THEIR PRECURSOR2 | May 2020 | March 2021 | Allow | 10 | 0 | 0 | No | No |
| 16762724 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | May 2020 | May 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 16869961 | INJECTABLE FORMULATIONS FOR TREATING CANCER | May 2020 | May 2021 | Abandon | 12 | 1 | 0 | No | No |
| 16869848 | COMPOSITIONS AND METHODS FOR SULFATION OF CARBOHYDRATES | May 2020 | May 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16866716 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | May 2020 | December 2022 | Abandon | 32 | 0 | 1 | No | No |
| 16865209 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | May 2020 | May 2021 | Allow | 12 | 1 | 0 | No | No |
| 16859722 | ENHANCED DELIVERY OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS | April 2020 | February 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 16857520 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | April 2020 | April 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 16854882 | RESIN COMPOSITION AND RESIN MOLDED PRODUCT | April 2020 | January 2023 | Allow | 33 | 1 | 1 | No | No |
| 16493450 | PROCESS FOR CONCENTRATING CELLS FROM A SAMPLE AND THEN ISOLATING NUCLEIC ACIDS FROM SAID CELLS | April 2020 | February 2023 | Allow | 41 | 1 | 0 | Yes | No |
| 16756851 | METHOD FOR ENRICHING PATHOGEN, USING HOMOBIFUNCTIONAL IMIDOESTER | April 2020 | April 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16846707 | POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY | April 2020 | August 2021 | Allow | 16 | 2 | 0 | No | No |
| 16843017 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | April 2020 | July 2022 | Allow | 27 | 1 | 1 | No | No |
| 16832413 | COMPOSITIONS AND METHODS FOR PREVENTING/TREATING METABOLIC SYNDROME | March 2020 | June 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16826908 | COMPOSITIONS AND METHODS THAT MODULATE BACTERIA IN A COMPANION ANIMAL | March 2020 | May 2021 | Allow | 14 | 2 | 0 | No | No |
| 16825121 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON | March 2020 | November 2021 | Allow | 20 | 1 | 0 | No | No |
| 16825337 | METHODS AND COMPOSITIONS FOR ADMINSTRATION OF IRON | March 2020 | February 2022 | Allow | 23 | 1 | 0 | No | No |
| 16824140 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY | March 2020 | August 2021 | Abandon | 17 | 1 | 1 | No | No |
| 16648146 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | March 2020 | July 2022 | Allow | 28 | 1 | 1 | No | No |
| 16821459 | CHITOSAN MATERIALS FROM CARBONIC ACID SOLUTION | March 2020 | November 2021 | Allow | 20 | 1 | 0 | No | No |
| 16646582 | Method for Using Aqueous Two-Phase System for the Isolation, Purification and/or Concentration of Short Nucleic Acid Fragments | March 2020 | November 2023 | Abandon | 44 | 4 | 1 | No | No |
| 16646243 | PENTOSAN POLYSULFATE AND METHOD FOR PRODUCING PENTOSAN POLYSULFATE | March 2020 | March 2022 | Allow | 25 | 2 | 1 | No | No |
| 16644614 | GLYCOSIDE COMPOUND OF FATTY ACIDS, COMPOSITION COMPRISING IT, PROCESS FOR ITS OBTENTION AND METHODS TO APPLY IT ON PLANTS OR FRUITS OR BOTH AT THE SAME TIME | March 2020 | December 2022 | Allow | 33 | 1 | 1 | No | No |
| 16800245 | TREATMENT OF BONE MARROW EDEMA (OEDEMA) WITH POLYSULFATED POLYSACCHARIDES | February 2020 | April 2022 | Allow | 25 | 1 | 1 | No | No |
| 16640005 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | February 2020 | December 2021 | Allow | 22 | 1 | 0 | No | No |
| 16790965 | TARGETING NAD+ TO TREAT CHEMOTHERAPY AND RADIOTHERAPY INDUCED COGNITIVE IMPAIRMENT, NEUROPATHIES AND INACTIVITY | February 2020 | March 2022 | Allow | 25 | 1 | 1 | No | No |
| 16790667 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY | February 2020 | August 2021 | Abandon | 18 | 1 | 1 | No | No |
| 16785498 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY | February 2020 | June 2021 | Allow | 16 | 1 | 1 | No | No |
| 16783622 | COMPOSITIONS COMPRISING GLUCOSE AND HEMICELLULOSE AND THEIR USE | February 2020 | August 2022 | Allow | 31 | 1 | 0 | No | No |
| 16779977 | CELLULOSE ESTER COMPOSITIONS DERIVED FROM RECYCLED PLASTIC CONTENT SYNGAS | February 2020 | May 2022 | Allow | 27 | 1 | 1 | No | No |
| 16776682 | Reagents Useful for Synthesizing Rhodamine-Labeled Oligonucleotides | January 2020 | April 2022 | Allow | 26 | 2 | 1 | No | No |
| 16634703 | TEMPO-CELLULOSE STRUCTURES AND RELATED METHODS | January 2020 | March 2024 | Allow | 50 | 4 | 0 | Yes | No |
| 16750094 | USE OF TREHALOSE FOR TREATMENT OF NEUROLOGICAL DISEASES | January 2020 | April 2021 | Allow | 15 | 1 | 1 | No | No |
| 16631014 | Combination Drug Therapy | January 2020 | February 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16630596 | ALKALI METAL SALT OF CARBOXYALKYL ETHER OF TAMARIND GUM WITH IMPROVED COMPOSITION | January 2020 | April 2022 | Allow | 27 | 1 | 0 | No | No |
| 16630372 | AMORPHOUS MIXTURE COMPRISING A NEUTRAL MONO- OR OLIGOSACCHARIDE AND AN ACIDIC NON-CARBOHYDRATE COMPONENT | January 2020 | July 2022 | Allow | 30 | 3 | 1 | No | No |
| 16733641 | METHODS FOR BIOBASED DERIVATIZATION OF CELLULOSIC SURFACES | January 2020 | March 2021 | Allow | 14 | 1 | 1 | No | No |
| 16730717 | USE OF BENZOPYRAN COMPOUND IN PREPARATION OF PRODUCT FOR REGULATING LIPID METABOLISM AND COMPOSITION OF THE SAME | December 2019 | July 2021 | Abandon | 19 | 1 | 1 | No | No |
| 16728400 | AMYLASE-DEGRADED ORGANIC ACID ANHYDRIDE SUBSTITUTED STARCHES AND METHODS OF PREPARING THE SAME | December 2019 | October 2021 | Allow | 22 | 1 | 1 | No | No |
| 16725659 | Polynucleotide Purification Agents and Related Methods | December 2019 | December 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16724654 | SYNTHESIS OF DESOSAMINES | December 2019 | January 2021 | Allow | 12 | 0 | 1 | No | No |
| 16720899 | ENZYME-DIRECTED IMMUNOSTIMULANT AND USES THEREOF | December 2019 | May 2021 | Allow | 17 | 1 | 1 | No | No |
| 16719391 | Thermally Inhibited Starch and Process for Making | December 2019 | June 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16623984 | Improved Process for Preparing Imetelstat | December 2019 | June 2021 | Allow | 18 | 0 | 0 | No | No |
| 16715857 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF BLADDER CANCER WITH OXALIPLATIN | December 2019 | March 2021 | Allow | 15 | 1 | 0 | No | No |
| 16622446 | PROCESS FOR PREPARING A POOLED HUMAN PLATELET LYSATE, POOLED HUMAN PLATELET LYSATE AND ITS USE FOR TREATING NEUROLOGICAL DISORDERS | December 2019 | February 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16621833 | MANUFACTURE OF HYDROPHOBIZED NANOCELLULOSE INTERMEDIATE AS WELL AS HYDROPHOBIZED NANOCELLULOSE | December 2019 | July 2021 | Allow | 19 | 1 | 1 | No | No |
| 16621949 | USE OF CIMICIFUGAE RHIZOMA TRITERPENOID SAPONIN EXTRACT, ACTEIN, AND DEOXYACTEIN | December 2019 | March 2021 | Allow | 15 | 1 | 0 | No | No |
| 16620900 | NOVEL INTERMEDIATES FOR THE PREPARATION OF GBS POLYSACCHARIDE ANTIGENS | December 2019 | June 2024 | Abandon | 55 | 1 | 1 | No | No |
| 16703397 | BIOFILM PENETRATING COMPOSITIONS AND METHODS | December 2019 | July 2020 | Allow | 8 | 0 | 1 | Yes | No |
| 16694979 | HYALURONIC ACID FORMULATION CONTAINING PYRUVATE | November 2019 | March 2021 | Allow | 16 | 1 | 0 | No | No |
| 16689002 | METHODS AND COMPOSITIONS FOR PREPARING NUCLEIC ACIDS THAT PRESERVE SPATIAL-PROXIMAL CONTIGUITY INFORMATION | November 2019 | April 2022 | Allow | 29 | 1 | 1 | No | No |
| 16683996 | METHOD OF USING ASTAXANTHIN FOR THE TREATMENT OF DISEASES, AND MORE PARTICULARLY, THE TREATMENT OF CANCER | November 2019 | April 2021 | Allow | 17 | 1 | 1 | No | No |
| 16611558 | A PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS AND INTERMEDIATES THEREOF | November 2019 | January 2022 | Allow | 27 | 2 | 0 | No | No |
| 16656129 | METHODS AND COMPOSITIONS FOR TREATING ORAL MUCOSITIS | October 2019 | March 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16605257 | FUCOSE SEPARATION METHOD AND APPARATUS THEREFOR | October 2019 | January 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16590954 | STARCH-DERIVED CLATHRATE-FORMING COMPOSITIONS | October 2019 | February 2022 | Allow | 28 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LAU, JONATHAN S.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LAU, JONATHAN S works in Art Unit 1623 and has examined 512 patent applications in our dataset. With an allowance rate of 54.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner LAU, JONATHAN S's allowance rate of 54.3% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LAU, JONATHAN S receive 1.64 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LAU, JONATHAN S is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -28.3% benefit to allowance rate for applications examined by LAU, JONATHAN S. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 49.2% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 70.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 27% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.2% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.